XML 22 R12.htm IDEA: XBRL DOCUMENT
v3.24.1.1.u2

ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE | 9 Months Ended
--- | ---
Mar. 31, 2024
Receivables [Abstract] |
ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE | NOTE 3 – ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE Receivables, net is comprised of the following at March 31, 2024, and June 30, 2023:
Schedule of financing receivable noncurrent allowance for credit loss |  |  |  |  |  |  |  |  |  |  |  |
|  | March 31, 2024
|  | Gross Receivable |  | Allowance for credit losses |  | Net
Accounts receivable |  | $ | 3,484 |  |  | $ | 175 |  |  | $ | 3,309 |
Accounts receivable - related party |  | $ | 30 |  |  |  | — |  |  | $ | 30 |
Medical receivable |  | $ | 23,583 |  |  | $ | — |  |  | $ | 23,583 |
Management and other fees receivable |  | $ | 53,358 |  |  | $ | 12,404 |  |  | $ | 40,954 |
Management and other fees receivable from related medical practices (“PC’s”) |  | $ | 15,458 |  |  | $ | 5,868 |  |  | $ | 9,590 |
|  | June 30, 2023
|  | Gross Receivable |  | Allowance for credit losses |  | Net
Accounts receivable |  | $ | 4,060 |  |  | $ | 199 |  |  | $ | 3,861 |
Medical receivable |  | $ | 21,259 |  |  | $ | — |  |  | $ | 21,259 |
Management and other fees receivable |  | $ | 48,497 |  |  | $ | 12,609 |  |  | $ | 35,888 |
Management and other fees receivable from related medical practices (“PC’s”) |  | $ | 13,152 |  |  | $ | 3,990 |  |  | $ | 9,162 |
The Company’s customers are concentrated in the healthcare industry. Accounts Receivable Credit risk with respect to the Company’s accounts receivable related to product sales and service and repair fees is limited due to the customer advances received prior to the commencement of work performed and the billing of amounts to customers as sub-assemblies are completed. Service and repair fees are billed on a monthly or quarterly basis and the Company does not continue providing these services if accounts receivable become past due. The Company controls credit risk with respect to accounts receivable from service and repair fees through its credit evaluation process, credit limits, monitoring procedures and reasonably short collection terms. The Company performs ongoing credit authorizations before a product sales contract is entered into or service and repair fees are provided. Long Term Accounts Receivable Long term accounts receivable balances at March 31, 2024 and June 30, 2023 amounted to approximately $576 and $710, respectively. The Company will generate revenue from long-term, non-cancellable contracts to provide service and repair services. Future revenue to be recognized over the following two years as of March 31, 2024 is as follows:
Schedule of Future revenue |  |  |  |
2026 |  |  | $ | 406
2027 |  |  |  | 166
Total |  |  | $ | 572
Medical Receivables Medical receivables are due under fee-for-service contracts from third party payors, such as hospitals, government sponsored healthcare programs, patient’s legal counsel and directly from patients. Substantially all the revenue relates to patients residing in Florida. The carrying amount of the medical receivable is reduced by an allowance that reflects management’s best estimate of the amounts that will not be collected. The Company determines allowances for contractual adjustments and uncollectible accounts based on specific agings, specific payor collection issues that have been identified and based on payor classifications and historical experience at each site. Management and Other Fees Receivable The Company’s receivables from the related and non-related professional corporations (PC’s) substantially consist of fees outstanding under management agreements. Payment of the outstanding fees is dependent on collection by the PC’s of fees from third party medical reimbursement organizations, principally insurance companies and health management organizations. Payment of the management fee receivables from the PC’s may be impaired by the inability of the PC’s to collect in a timely manner their medical fees from the third-party payors, particularly insurance carriers covering automobile no-fault and workers compensation claims due to longer payment cycles and rigorous informational requirements and certain other disallowed claims. Approximately 66.8% and 67.6% of the PCs’ net revenues for the three months ended March 31, 2024 and 2023, respectively, were derived from no-fault and personal injury protection claims. Approximately 66.8% and 67.9% of the PCs’ net revenue for the nine months ended March 31, 2024 and 2023, respectively, were derived from no-fault and personal injury protection claims. The Company considers the aging of its accounts receivable in determining the amount of allowance for credit losses. The Company generally takes all legally available steps to collect its receivables. Credit losses associated with the receivables are provided for in the condensed consolidated financial statements and have historically been within management’s expectations. Net revenues from management and other fees charged to the related PCs accounted for approximately 11.6% and 11.7% of the consolidated net revenues for the three months ended March 31, 2024 and 2023, respectively. Net revenues from management and other fees charged to the related PCs accounted for approximately 11.6% and 12.3% of the consolidated net revenues for the nine months ended March 31, 2024 and 2023, respectively. Tallahassee Magnetic Resonance Imaging, Inc., Stand Up MRI of Boca Raton, Inc. and Stand Up MRI & Diagnostic Center, Inc. (all related medical practices) entered into a guaranty agreement, pursuant to which they cross guaranteed all management fees which are payable to the Company, which have arisen under each individual management agreement. Additional Company managed entities also operate under a guaranty agreement, pursuant to which management fees are payable to the Company. The Company’s patient fee revenue, net of contractual allowances and discounts for the three and nine months ended March 31, 2024 and 2023 are summarized in the following table.
Schedule of patient fee revenue |  |  |  |  |  |  |  |
|  | For the Three Months Ended March 31,
|  | 2024 |  | 2023
Commercial Insurance/ Managed Care |  | $ | 1,258 |  |  | $ | 1,037 |
Medicare/Medicaid |  |  | 314 |  |  |  | 303 |
Workers’ Compensation/Personal Injury |  |  | 5,073 |  |  |  | 5,186 |
Other |  |  | 1,969 |  |  |  | 1,662 |
Patient Fee Revenue, net of contractual allowances and discounts |  | $ | 8,614 |  |  | $ | 8,188 |
|  | For the Nine Months Ended March 31,
|  | 2024 |  | 2023
Commercial Insurance/ Managed Care |  | $ | 3,674 |  |  | $ | 2,905 |
Medicare/Medicaid |  |  | 869 |  |  |  | 788 |
Workers’ Compensation/Personal Injury |  |  | 15,117 |  |  |  | 13,683 |
Other |  |  | 5,851 |  |  |  | 4,017 |
Patient Fee Revenue, net of contractual allowances and discounts |  | $ | 25,511 |  |  | $ | 21,393 |

X
- Definition The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//310-10/tableOfContent + Details
Name: | us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_ReceivablesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration